Donate
Email Password
Not a member? Sign Up   Forgot password?
Business and Economics Education Environment Health Care California
Home
About PRI
My PRI
Contact
Search
Policy Research Areas
Events
Publications
Press Room
PRI Blog
Jobs Internships
Scholars
Staff
Book Store
Policy Cast
Upcoming Events
WSJ's Stephen Moore Book Signing Luncheon-Rescheduled for December 17
12.17.2012 12:00:00 PM
Who's the Fairest of Them All?: The Truth About Opportunity, ... 
More

Recent Events
Victor Davis Hanson Orange County Luncheon December 5, 2012
12.5.2012 12:00:00 PM

Post Election: A Roadmap for America's Future

 More

Post Election Analysis with George F. Will & Special Award Presentation to Sal Khan of the Khan Academy
11.9.2012 6:00:00 PM

Pacific Research Institute Annual Gala Dinner

 More

Reading Law: The Interpretation of Legal Texts
10.19.2012 5:00:00 PM
Author Book Signing and Reception with U.S. Supreme Court Justice ... More

Opinion Journal Federation
Town Hall silver partner
Lawsuit abuse victims project
Press Archive
E-mail Print Side effects
Boston Herald
By: Lawrence J. McQuillan, Ph.D
11.5.2008

Boston Herald, November 5, 2008
Los Angeles Times, November 8, 2008
San Francisco Examiner, November 9, 2008

 

U.S. Tort Liability Index: 2008
Letter to the Editor

The health of all Americans is at stake as the U.S. Supreme Court weighs the arguments in Wyeth vs. Levine (“U.S. court hears amputee’s case in drug suit,” Nov. 3). If the high court overturns the supremacy - or “pre-emption” - of federal laws over state ones, personal-injury lawyers will unleash a torrent of frivolous lawsuits to the detriment of public health.

Patients would see the price of life-saving medicines rise as the availability of medicines dwindled. Those hoping for new cures would be left in the lurch, as companies would be forced to divert money from R&D to legal costs.

A verdict against Wyeth would also make local judges and juries the de facto drug regulators in this country, rather than scientific experts at the FDA. Instead of one set of drug-safety regulations, we'd eventually have 50 conflicting standards, one for each state. Such a fractured regulatory apparatus would harm development of new drugs and hurt all Americans.


Lawrence McQuillan,
Director Business and Economic Studies
Pacific Research Institute San Francisco

Related Link
Submit to: 
Submit to: Digg Submit to: Del.icio.us Submit to: Facebook Submit to: StumbleUpon Submit to: Newsvine Submit to: Reddit
Within Press
Browse by
Recent Publications
Press Archive
Powered by eResources